--- title: "Popular pre-market trades in US stocks: Banco Santander Brasil up 7.51% in pre-market; DexCom up 7.45% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/294486692.md" description: "Banco Santander Brasil pre-market up 7.51%; DexCom pre-market up 7.45%; Microbus pre-market up 285.33%; Replimune pre-market up 110.17%; Mangoceuticals pre-market up 83.17%" datetime: "2026-07-31T09:18:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294486692.md) - [en](https://longbridge.com/en/news/294486692.md) - [zh-HK](https://longbridge.com/zh-HK/news/294486692.md) --- # Popular pre-market trades in US stocks: Banco Santander Brasil up 7.51% in pre-market; DexCom up 7.45% in pre-market **Pre-market Hot Trades in US Stocks** Banco Santander Brasil pre-market up 7.51%. Based on recent key news: 1. On July 30, Banco Santander Brasil released its second-quarter financial report, with a net profit of 3 billion reais, lower than analysts' expectations of 3.9 billion reais. Nevertheless, the market remains optimistic about its long-term growth potential, driving the stock price up. 2. On July 30, Banco Santander announced a voluntary tender offer that could lead to its Brazilian ADS being delisted from the New York Stock Exchange. This transaction is believed to increase earnings per share while maintaining capital neutrality, further boosting investor confidence. 3. On July 29, Banco Santander Brasil's average return on equity (ROAE) was 12.5%, although lower than 16.4% in the same period last year, it showed resilience through efficiency improvements and digital initiatives, supporting the stock price increase. The long-term growth potential in the Brazilian market is strong, enhancing investor confidence. DexCom pre-market up 7.45%. Based on recent key news: 1. On July 31, DexCom announced its second-quarter results, with revenue increasing approximately 13% year-over-year to $1.31 billion, exceeding market expectations of $1.29 billion. Adjusted earnings per share were $0.70, also surpassing market expectations of $0.61. The company also raised the lower end of its full-year revenue guidance, expecting revenue to be between $5.18 billion and $5.25 billion, up from a previous expectation of $5.16 billion to $5.25 billion, with market expectations at $5.22 billion. This news drove the stock price up. Source: Guandian.com 2. On July 31, DexCom's gross margin increased to approximately 64%, up from 63%. The company achieved this improvement in gross margin by increasing production and manufacturing efficiency of G7 15-day products, despite facing costs related to the phase-out of G6 products. This news further enhanced market confidence. Source: Reuters 3. On July 31, DexCom announced it would collaborate with activist investor Elliott Investment Management to appoint two independent directors and restructure key board committees. This move is seen as a positive signal for corporate governance improvement, further driving the stock price up. Source: Reuters The healthcare industry is experiencing strong growth, with significant policy support. **Top Gainers in US Pre-market Stocks** WeBus pre-market up 285.33%. Based on recent key news: 1. On July 30, Wetour Robotics announced a stock consolidation plan with a consolidation ratio of 1 to 100, expected to take effect on August 3. This move may lead to a reassessment of its stock by the market, driving stock price volatility. 2. On July 29, the SEC issued a statement reminding investors to be cautious about forward-looking statements. Such statements may affect investor confidence, leading to stock price volatility On July 29, Fermi and Galaxy Digital faced challenges amid changes in cryptocurrency regulation, with investor interest in risk assets fluctuating. Such macroeconomic factors may affect the market performance of related stocks. Changes in cryptocurrency regulation impact market sentiment. Replimune surged 110.17% in pre-market trading. Based on recent key news: 1. On July 30, Replimune announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee had favorable results regarding the review of RP1 for advanced melanoma. This news significantly boosted the stock price. Source: Reuters 2. On July 28, FDA reviewers expressed concerns about Replimune's RP1 drug trial, stating that the trial failed to provide sufficient evidence of efficacy, leading to a 21% drop in the stock price in pre-market trading. Source: Reuters 3. On July 28, FDA documents indicated that the RP1 drug faced regulatory challenges, with BMO analysts noting concerns about the drug's component contributions and the heterogeneity of the treatment population, causing the stock price to drop 33.26% during trading. Source: Zhitong Finance. The biopharmaceutical industry faces regulatory challenges, and market volatility has intensified. Mangoceuticals rose 83.17% in pre-market trading. Based on recent news: 1. On July 30, Mangoceuticals announced new product releases, significantly boosting the stock price. The company detailed the market potential and expected returns of the new products in a release via GlobeNewswire, attracting investor attention and leading to an 83.17% increase in pre-market stock price. 2. On July 29, market expectations for Mangoceuticals' future growth strengthened, further driving up the stock price. Analysts expressed optimism about the market acceptance of the company's new products, believing they would significantly enhance the company's performance. 3. On July 28, Mangoceuticals' stock price was positively influenced by the overall favorable industry outlook. With increased policy support and market demand in the biotechnology sector, investor confidence in the industry has strengthened, driving up the stock prices of related companies. The biotechnology sector has performed strongly recently, with clear policy support ### Related Stocks - [BSBR.US](https://longbridge.com/en/quote/BSBR.US.md) - [DXCM.US](https://longbridge.com/en/quote/DXCM.US.md) - [WETO.US](https://longbridge.com/en/quote/WETO.US.md) - [REPL.US](https://longbridge.com/en/quote/REPL.US.md) - [MGRX.US](https://longbridge.com/en/quote/MGRX.US.md) ## Related News & Research - [Santander Brasil Expands Board to Thirteen Directors After August EGM](https://longbridge.com/en/news/296278674.md) - [Santander Brasil holds extraordinary shareholder meeting voting session](https://longbridge.com/en/news/296401622.md) - [Banco Santander Brasil announces extraordinary shareholders meeting](https://longbridge.com/en/news/296146498.md) - [Santander plans exchange offers to buy remaining minority stake in Santander Brasil](https://longbridge.com/en/news/295981286.md) - [Major Insider Moves Shake Up Banco Santander Brasil Stock](https://longbridge.com/en/news/295876687.md)